Targeting cancer with Click Chemistry

Less than 2% of administered drugs make it to their desired location in the body. Imagine a world where cancer drugs are activated only where they are needed.

Let's do better

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.

Here's how

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.

Antigen-targeted activator

Binds to the tumor

Protodrugs

Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.

A new approach

Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This unprecedented flexibility can lead to greater activity and lower toxicity than has been previously possible.

CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.

Our science

Latest news

2024 - AACR

Apr 10, 2024

conference

Improving anti-tumor efficacy by modulating a separate HER2 activator and an MMAE payload and reuniting both through click chemistry

2024 - AACR

Apr 10, 2024

conference

A click chemistry-based HER2 targeting agent activates a decoupled MMAE payload making it highly differentiated in efficacy and safety than ADCs

2024 - AACR

Apr 10, 2024

conferences

Tumor targeted activation of an attenuated exatecan protodrug through Click Chemistry demonstrates efficacy in murine tumor studies

Targeting cancer with Click Chemistry

Less than 2% of administered drugs make it to their desired location in the body. Imagine a world where cancer drugs are activated only where they are needed.

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.

Antigen-targeted activator

Binds to the tumor

Protodrugs

Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.

Changing what's possible

Latest news

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?

Interested in exploring a collaboration?

Targeting cancer with Click Chemistry

Less than 2% of administered drugs make it to their desired location in the body. Imagine a world where cancer drugs are activated only where they are needed.

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor. We are the first company to use click chemistry in human patients.

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.

Antigen-targeted activator

Binds to the tumor

Protodrugs

Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.

Changing what's possible

Latest news

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?

Interested in exploring a collaboration?

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.